Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria
Top Cited Papers
Open Access
- 15 November 2016
- Vol. 72 (4), 519-533
- https://doi.org/10.1111/all.13083
Abstract
The monoclonal anti‐immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1‐antihistamine treatment. Omalizumab binds to free IgE, which lowers free IgE levels and causes FcεRI receptors on basophils and mast cells to be downregulated. It has been shown to improve symptoms of CIU/CSU, but its mechanism of action is not currently understood. Potential mechanisms in CIU/CSU include reducing mast cell releasability, reversing basopenia and improving basophil IgE receptor function, reducing activity of IgG autoantibodies against FcεRI and IgE, reducing activity of IgE autoantibodies against an antigen or autoantigen that has yet to be definitively identified, reducing the activity of intrinsically ‘abnormal’ IgE, and decreasing in vitro coagulation abnormalities associated with disease activity. However, none of these theories alone or in combination fully account for the pattern of symptom improvement seen with omalizumab therapy, and therefore, no one mechanism is likely to be the definitive mechanism of action. Additional research is needed to further clarify the involvement of omalizumab in relieving symptoms associated with the complex, multifactorial pathogenesis of CIU/CSU.Keywords
Funding Information
- Novartis Pharmaceuticals Corporation
- Genentech
This publication has 140 references indexed in Scilit:
- Chronic urticaria and autoimmunity: Associations found in a large population studyJournal of Allergy and Clinical Immunology, 2012
- Clinical and laboratory features of antihistamine-resistant chronic idiopathic urticariaAllergy and Asthma Proceedings, 2011
- Omalizumab is effective in nonautoimmune urticariaJournal of Allergy and Clinical Immunology, 2011
- IgE Mediated Autoallergy against Thyroid Peroxidase – A Novel Pathomechanism of Chronic Spontaneous Urticaria?PLOS ONE, 2011
- Regulation of Syk kinase and FcRβ expression in human basophils during treatment with omalizumabJournal of Allergy and Clinical Immunology, 2010
- Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challengeJournal of Allergy and Clinical Immunology, 2010
- Reduced FcεRI-Mediated Release of Asthma-Promoting Cytokines and Chemokines from Human Basophils during Omalizumab TherapyInternational Archives of Allergy and Immunology, 2009
- Cultured peripheral blood mast cells from chronic idiopathic urticaria patients spontaneously degranulate upon IgE sensitization: Relationship to expression of Syk and SHIP-2Clinical Immunology, 2009
- New concepts in chronic urticariaCurrent Opinion in Immunology, 2008
- Passive transfer of cold urticariaJournal of Allergy, 1950